Bejelentkezés Regisztrálj ingyen

Acelrx Pharmaceuticals Inc Ret. a saját tőke

Mi az Acelrx Pharmaceuticals Inc Ret. a saját tőke?

A Ret. a saját tőke az Acelrx Pharmaceuticals Inc - -131.91%

Mi a Ret. a saját tőke meghatározása?



A saját tőke megtérülése egy vállalkozás nyereségességének mértéke a részvényes saját tőkéjének könyv szerinti értékéhez viszonyítva. Ezt úgy számítják ki, hogy a pénzügyi év nettó eredményét a teljes részvényes tőkével osztják el.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. a saját tőke a Health Care szektor a NASDAQ-on cégekben a Acelrx Pharmaceuticals Inc -hoz képest

Mit csinál Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

ret. a saját tőke -hoz hasonló cégek Acelrx Pharmaceuticals Inc